跳至主要内容
临床试验/NL-OMON48558
NL-OMON48558已完成不适用

GIGA Study: Gastrointestinal benefit of dairy Ingredients to prevent symptoms of Gut infection in healthy Adult subjects - GIGA

FrieslandCampina Nederland BV0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 2. Age between 18 and 55 years.
  • 3. BMI *18.5 and *30.0 kg/m2.
  • 4. Healthy as assessed by the NIZO food research medical questionnaire.

排除标准

  • 1. Acute gastroenteritis in the 2 months prior to inclusion.
  • 2. Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus infection (HIV).
  • 3. Disease of the GI tract, liver, bile bladder, kidney, thyroid gland (self-reported), except for appendicitis.
  • 4. History of microbiologically confirmed ETEC or cholera infection within 3 years prior to inclusion.
  • 5. Symptoms consistent with Travelers' Diarrhea concurrent with travel to countries where ETEC infection is endemic (most of the developing world) within 3 years prior to inclusion, OR planned travel to endemic countries during the length of the study.
  • 6. Vaccination for, or ingestion of cholera within 3 years prior to inclusion, including studies at NIZO.
  • 7. Occupation involving handling of ETEC or Vibrio cholerae currently, or within 3 years prior to inclusion.
  • 8. Vaccination for, or ingestion of ETEC or E coli heat labile toxin, including E. coli challenge studies at NIZO.
  • 9. Evidence of current excessive alcohol consumption (>4 consumptions/day or >20 consumptions/week) or drug (ab)use, and not willing/able to stop this during the study.
  • 10. Known allergy to the following antibiotics: ciprofloxacin, trimethoprim, sulfamethoxazole, and penicillins.
  • 11. Reported average stool frequency of >3 per day or <1 per 2 days.
  • 12. Use of antibiotics (up till 6 months prior to inclusion), norit, laxatives, cholestyramine, antacids H2 receptor antagonists or proton pump inhibitors (during 3 months prior to inclusion).
  • 13. Use of immunosuppressive drugs (e.g. cyclosporine, azathioprine, systemic corticosteroids, antibodies).
  • 14. Vegans.
  • 15. Mental status that is incompatible with the proper conduct of the study.
  • 16. A self-reported milk allergy, lactose intolerance or sensitivity to dairy ingredients.;For the subgroup of participants for exhaled breath analysis, the following additional exclusion criterion applies for participation in the VOC feasibility analysis:
  • History of or current self-reported or doctor-diagnosed disease of the lungs, such as asthma or COPD.

研究者

相似试验